Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.
Plasma concentrations of perphenazine (PPZ) (Trilafon) and perphenazinesulphoxide (PPZSO) were estimated during a 2-week period in 16 patients receiving peroral PPZ treatment for various psychotic disorders. The results demonstrated that the average concentration of three plasma samples was a reasonably good expression of the steady-state plasma level despite a great fluctuation in the concentration from sample to sample. Increased doses in three of the patients resulted in disproportionate increases in the plasma levels. Neurological side effects were recorded and their relation to plasma concentrations are discussed.
D000284:Administration, Oral; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010546:Perphenazine / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy; D013454:Sulfoxides / Q000097:blood; D013997:Time Factors
D013454:Sulfoxides; D010546:Perphenazine